<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777970</url>
  </required_header>
  <id_info>
    <org_study_id>DEX-TRA-06</org_study_id>
    <nct_id>NCT02777970</nct_id>
  </id_info>
  <brief_title>Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar</brief_title>
  <acronym>DAVID</acronym>
  <official_title>Analgesic Efficacy of Oral Dexketoprofen Trometamol/Tramadol Hydrochloride Versus Tramadol Hydrochloride/Paracetamol: a Randomised, Double-blind, Placebo and Active-controlled, Parallel Group Study in Moderate to Severe Acute Pain After Removal of Impacted Lower Third Molar (Dexketoprofen Analgesic eVolution wIth tramaDol- DAVID Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to evaluate the analgesic efficacy of TRAM.HCl/DKP.TRIS 75mg/25mg oral&#xD;
      fixed drug combination in comparison with TRAM.HCl /paracetamol 75mg/650mg in the treatment&#xD;
      of moderate to severe acute pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present phase IV study is a randomised, double-blind, placebo and active-controlled,&#xD;
      parallel group study in moderate to severe acute pain after removal of impacted lower third&#xD;
      molar.&#xD;
&#xD;
      In this single-dose clinical trial patients are randomized to the following 3 treatment arms&#xD;
      in a 2:2:1 ratio:&#xD;
&#xD;
        -  TRAM.HCL/DKP.TRIS&#xD;
&#xD;
        -  Paracetamol/TRAM.HCL&#xD;
&#xD;
        -  Placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">February 14, 2017</completion_date>
  <primary_completion_date type="Actual">February 14, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose)</measure>
    <time_frame>6 hours post-dose</time_frame>
    <description>TOTPAR calculated as the weighted sum of the PAR scores, measured according to a 5-point VRS (Verbal Rating Scale) from 0=no relief to 4=complete relief, over 6 hours post-dose (TOTPAR6).&#xD;
The TOTPAR6 ranges from a minimum of 0 to a maximum of 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of Patients Achieving 50% of Max TOTPAR</measure>
    <time_frame>8 hours post-dose</time_frame>
    <description>Percentage of patients who achieved at least 50% of the maximum TOTPAR at 8 hours. In the present trial the achievable TOTPAR over 8 hours ranges between 0 and 32.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose</measure>
    <time_frame>8 hours post-dose</time_frame>
    <description>Percentage of patients who achieve at least 30% of PI Reduction versus baseline Over 8 Hours Post-dose. Percentage change of PI is calculated using the baseline value minus the PI assessed at 8 hours post-dose divided for the baseline value, then multiplied for 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Confirmed FPPAR (First Perceptible Pain Relief)</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Time to confirmed FPPAR (time to onset of analgesia) - i.e. time to FPPAR if confirmed by experiencing Meaningful Pain Relief (MPAR)&#xD;
FPPAR and MPAR assessed by using stopwatches:&#xD;
'first perceptible' PAR (FPPAR), i.e, at the moment they first felt any PAR whatsoever;&#xD;
'meaningful' PAR (MPAR, ie, when the relief from pain became meaningful to them)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Patients Requiring RM (Rescue Medication)</measure>
    <time_frame>8 hours post-dose</time_frame>
    <description>Percentage of patients who required RM within the first over 8 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGE (Patient Global Evaluation)</measure>
    <time_frame>8 hours postdose</time_frame>
    <description>PGE of the study medication (measured according to a five-point VRS from 1 = poor to 5 = excellent) at 8 hours post-dose or whenever the patient uses Rescue Medication (RM).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">654</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Tramadol/Dexketoprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol/Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.&#xD;
.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;&#xD;
Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Hydrochloride/Dexketoprofen Trometamol</intervention_name>
    <arm_group_label>Tramadol/Dexketoprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Hydrochloride/Paracetamol</intervention_name>
    <arm_group_label>Tramadol/Paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tramadol/Dexketoprofen</arm_group_label>
    <arm_group_label>Tramadol/Paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged more than 18 years. Females participating in the study&#xD;
             must be either non-childbearing potential or routinely using an effective method of&#xD;
             birth control resulting in a low failure rate.&#xD;
&#xD;
          -  Scheduled for outpatient surgical extraction -under local anaesthesia of lower third&#xD;
             molar teeth, with at least one partially impacted in the mandible requiring bone&#xD;
             manipulation.&#xD;
&#xD;
          -  Pain of at least moderate intensity in the first 4 hours after the end of surgery (NRS&#xD;
             score ≥ 4).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy or hypersensitivity to the study treatments, RM or to any other&#xD;
             NSAIDs, opioids and acetyl salicylic acid.&#xD;
&#xD;
          -  History of peptic ulcer, gastrointestinal disorders by NSAIDs or gastrointestinal&#xD;
             bleeding or other active bleedings.&#xD;
&#xD;
          -  History of any illness or condition that, in the opinion of the Investigator might&#xD;
             pose a risk to the patient or confound the efficacy and safety results of the study.&#xD;
&#xD;
          -  Patients using and not suitable for withdrawing the prohibited medications specified&#xD;
             in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Tóth Bagi Zoltán Fogászati Rendeloje</name>
      <address>
        <city>Budapest</city>
        <zip>1052</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OralMed Studio Fogászati és Szájsebészeti Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1126</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile San Salvatore di L'Aquila</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ars-Dent</name>
      <address>
        <city>Bialystok</city>
        <zip>15-078</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Stomatologiczny Andrzej Wojtowicz AW Clinic</name>
      <address>
        <city>Warszawa</city>
        <zip>00-852</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charme Clinique Klinika Stomatologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-670</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Teknon</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Médico Quirúrgico de Conxo</name>
      <address>
        <city>La Coruna</city>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Community Healthcare NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6FH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of North Midlands NHS Trust</name>
      <address>
        <city>Stoke on Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <results_first_submitted>December 10, 2020</results_first_submitted>
  <results_first_submitted_qc>March 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2021</results_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute pain</keyword>
  <keyword>Acute moderate to severe pain</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Dexketoprofen Tramadol</keyword>
  <keyword>Dexketoprofen trometamol</keyword>
  <keyword>Tramadol hydrochloride</keyword>
  <keyword>Multimodal analgesia</keyword>
  <keyword>Third molar extraction</keyword>
  <keyword>Fixed drug combination</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Analgesics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Dexketoprofen trometamol</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 24, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT02777970/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT02777970/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in 18 centers across 5 European countries: Hungary, Italy, Poland, Spain and the United Kingdom. The clinical phase of the study started on 28th April 2016 (first screened patient) and concluded on 14th February 2017 (last patient out).</recruitment_details>
      <pre_assignment_details>A total of 792 patients were screened, of which 654 patients were randomized. One randomized patient was excluded from all the analysis populations, because of being younger than 18 years old. Prior to randomization, enrolled patients underwent a Screening period lasting up 2 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tramadol/Dexketoprofen</title>
          <description>Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose.</description>
        </group>
        <group group_id="P2">
          <title>Tramadol/Paracetamol</title>
          <description>Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;&#xD;
Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="262"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="261"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat (ITT) population: all patients randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Tramadol/Dexketoprofen</title>
          <description>Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose.</description>
        </group>
        <group group_id="B2">
          <title>Tramadol/Paracetamol</title>
          <description>Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;&#xD;
Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="260"/>
            <count group_id="B2" value="262"/>
            <count group_id="B3" value="131"/>
            <count group_id="B4" value="653"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="7.48"/>
                    <measurement group_id="B2" value="27.1" spread="8.13"/>
                    <measurement group_id="B3" value="26.5" spread="7.67"/>
                    <measurement group_id="B4" value="26.9" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="309"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or Afro-american</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Intensity at Qualification</title>
          <description>Patients rate their pain intensity (PI) on e-Diary using an 11-point Numerical Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst pain). This PI-NRS does not include subscales.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" spread="1.19"/>
                    <measurement group_id="B2" value="4.9" spread="1.12"/>
                    <measurement group_id="B3" value="4.8" spread="1.10"/>
                    <measurement group_id="B4" value="4.9" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose)</title>
        <description>TOTPAR calculated as the weighted sum of the PAR scores, measured according to a 5-point VRS (Verbal Rating Scale) from 0=no relief to 4=complete relief, over 6 hours post-dose (TOTPAR6).&#xD;
The TOTPAR6 ranges from a minimum of 0 to a maximum of 24.</description>
        <time_frame>6 hours post-dose</time_frame>
        <population>A total of 654 patients were randomized and received the study treatments, of these one underage patient, erroneously enrolled in the study, was excluded from all the analysis populations, therefore 653 patients constituted ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Dexketoprofen</title>
            <description>Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Paracetamol</title>
            <description>Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;&#xD;
Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose)</title>
          <description>TOTPAR calculated as the weighted sum of the PAR scores, measured according to a 5-point VRS (Verbal Rating Scale) from 0=no relief to 4=complete relief, over 6 hours post-dose (TOTPAR6).&#xD;
The TOTPAR6 ranges from a minimum of 0 to a maximum of 24.</description>
          <population>A total of 654 patients were randomized and received the study treatments, of these one underage patient, erroneously enrolled in the study, was excluded from all the analysis populations, therefore 653 patients constituted ITT population.</population>
          <units>5-point Verbal Rating Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="6.97"/>
                    <measurement group_id="O2" value="9.2" spread="7.65"/>
                    <measurement group_id="O3" value="1.9" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Patients Achieving 50% of Max TOTPAR</title>
        <description>Percentage of patients who achieved at least 50% of the maximum TOTPAR at 8 hours. In the present trial the achievable TOTPAR over 8 hours ranges between 0 and 32.&quot;</description>
        <time_frame>8 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Dexketoprofen</title>
            <description>Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Paracetamol</title>
            <description>Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;&#xD;
Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>% of Patients Achieving 50% of Max TOTPAR</title>
          <description>Percentage of patients who achieved at least 50% of the maximum TOTPAR at 8 hours. In the present trial the achievable TOTPAR over 8 hours ranges between 0 and 32.&quot;</description>
          <population>ITT population</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7"/>
                    <measurement group_id="O2" value="35.5"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose</title>
        <description>Percentage of patients who achieve at least 30% of PI Reduction versus baseline Over 8 Hours Post-dose. Percentage change of PI is calculated using the baseline value minus the PI assessed at 8 hours post-dose divided for the baseline value, then multiplied for 100.</description>
        <time_frame>8 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Dexketoprofen</title>
            <description>Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Paracetamol</title>
            <description>Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose; Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;&#xD;
Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>% of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose</title>
          <description>Percentage of patients who achieve at least 30% of PI Reduction versus baseline Over 8 Hours Post-dose. Percentage change of PI is calculated using the baseline value minus the PI assessed at 8 hours post-dose divided for the baseline value, then multiplied for 100.</description>
          <population>ITT population</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="35.5"/>
                    <measurement group_id="O3" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Confirmed FPPAR (First Perceptible Pain Relief)</title>
        <description>Time to confirmed FPPAR (time to onset of analgesia) - i.e. time to FPPAR if confirmed by experiencing Meaningful Pain Relief (MPAR)&#xD;
FPPAR and MPAR assessed by using stopwatches:&#xD;
'first perceptible' PAR (FPPAR), i.e, at the moment they first felt any PAR whatsoever;&#xD;
'meaningful' PAR (MPAR, ie, when the relief from pain became meaningful to them)</description>
        <time_frame>2 hours post-dose</time_frame>
        <population>The analysis is conducted only on active treatment arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Dexketoprofen</title>
            <description>Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose; Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Paracetamol</title>
            <description>Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose; Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Confirmed FPPAR (First Perceptible Pain Relief)</title>
          <description>Time to confirmed FPPAR (time to onset of analgesia) - i.e. time to FPPAR if confirmed by experiencing Meaningful Pain Relief (MPAR)&#xD;
FPPAR and MPAR assessed by using stopwatches:&#xD;
'first perceptible' PAR (FPPAR), i.e, at the moment they first felt any PAR whatsoever;&#xD;
'meaningful' PAR (MPAR, ie, when the relief from pain became meaningful to them)</description>
          <population>The analysis is conducted only on active treatment arms.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="17" upper_limit="23"/>
                    <measurement group_id="O2" value="24" lower_limit="20" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Patients Requiring RM (Rescue Medication)</title>
        <description>Percentage of patients who required RM within the first over 8 hours post-dose.</description>
        <time_frame>8 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Dexketoprofen</title>
            <description>Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose; Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Paracetamol</title>
            <description>Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose; Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;&#xD;
Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>% of Patients Requiring RM (Rescue Medication)</title>
          <description>Percentage of patients who required RM within the first over 8 hours post-dose.</description>
          <population>ITT population</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="55.0"/>
                    <measurement group_id="O3" value="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PGE (Patient Global Evaluation)</title>
        <description>PGE of the study medication (measured according to a five-point VRS from 1 = poor to 5 = excellent) at 8 hours post-dose or whenever the patient uses Rescue Medication (RM).</description>
        <time_frame>8 hours postdose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Dexketoprofen</title>
            <description>Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose; Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Paracetamol</title>
            <description>Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose; Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;&#xD;
Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.</description>
          </group>
        </group_list>
        <measure>
          <title>PGE (Patient Global Evaluation)</title>
          <description>PGE of the study medication (measured according to a five-point VRS from 1 = poor to 5 = excellent) at 8 hours post-dose or whenever the patient uses Rescue Medication (RM).</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.1"/>
                    <measurement group_id="O2" value="2.8" spread="1.4"/>
                    <measurement group_id="O3" value="1.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reported treatment emergent AEs (TEAEs) include events starting after administration of study drug on or after Day 1 and on or before end of study visit Day 6+/- 1.</time_frame>
      <desc>If an AE occurs for the first time or if it worsens after study drug intake it is classified as TEAE. If a subject experienced more than 1 of a given TEAE, the subject is counted only once for that TEAE.&#xD;
Overall 654 patients received the treatment, however one patient was excluded from all the analysis populations, because of being younger than 18 years old. Thus, the safety population accounts for 653 patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tramadol/Dexketoprofen</title>
          <description>Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose.</description>
        </group>
        <group group_id="E2">
          <title>Tramadol/Paracetamol</title>
          <description>Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose;&#xD;
Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;&#xD;
Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="262"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="260"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="262"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="260"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="262"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="262"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="262"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="260"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="262"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="262"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Angela Capriati (Clinical Sciences Director)</name_or_title>
      <organization>Menarini Ricerche</organization>
      <phone>+39 055 5680 ext 9933</phone>
      <email>acapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

